Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Monash IVF Group Ltd ( (AU:MVF) ) has provided an announcement.
Monash IVF Group has appointed Rebecca Dean as its new Company Secretary and General Counsel, effective 4 March 2026, strengthening its governance and legal capabilities across its assisted reproductive and women’s health services operations in Australia and Southeast Asia. Dean brings extensive experience in governance, compliance and corporate reporting from ASX-listed companies, including senior roles at SEEK and a 12-year tenure at Regis Healthcare, where she managed complex legal and regulatory issues in a highly regulated healthcare environment; the company’s CEO said her appointment is expected to deliver significant value for the business and stakeholders, with existing Company Secretary Malik Jainudeen retaining ASX communication responsibilities until her commencement.
The most recent analyst rating on (AU:MVF) stock is a Buy with a A$0.80 price target. To see the full list of analyst forecasts on Monash IVF Group Ltd stock, see the AU:MVF Stock Forecast page.
More about Monash IVF Group Ltd
Monash IVF Group Ltd is a leading provider of assisted reproductive services and specialist women’s imaging and diagnostic services, operating across Australia, Singapore, Malaysia and Indonesia. The company focuses on fertility treatment and women’s health in regulated healthcare markets in the Asia-Pacific region.
Average Trading Volume: 2,286,755
Technical Sentiment Signal: Strong Sell
Current Market Cap: A$292.2M
For detailed information about MVF stock, go to TipRanks’ Stock Analysis page.